CDYL2

Summary

CDYL2 (chromodomain Y like 2, HGNC:23030) is a protein-coding gene on chromosome 16q23.2, encoding Chromodomain Y-like protein 2 (Q8N8U2).

Predicted to enable transcription corepressor activity. Predicted to be involved in negative regulation of DNA-templated transcription. Predicted to be active in nucleus.

Source: NCBI Gene 124359 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 90 total
• Druggable target: yes
• MANE Select transcript: NM_152342

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23030
Approved symbol	CDYL2
Name	chromodomain Y like 2
Location	16q23.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ38866
Ensembl gene	ENSG00000166446
Ensembl biotype	protein_coding
OMIM	618816
Entrez	124359

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 5 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000561616, ENST00000562753, ENST00000562812, ENST00000563890, ENST00000566173, ENST00000567924, ENST00000570137, ENST00000919359

RefSeq mRNA: 1 — MANE Select: NM_152342 NM_152342

CCDS: CCDS32493

Canonical transcript exons

ENST00000570137 — 7 exons

Exon	Start	End
ENSE00001103030	80620763	80620935
ENSE00001103043	80612626	80612836
ENSE00001103046	80608092	80608235
ENSE00001185967	80684538	80685129
ENSE00001246763	80633019	80633236
ENSE00002591516	80804150	80804598
ENSE00002617613	80597907	80604546

Expression profiles

Bgee: expression breadth ubiquitous, 230 present calls, max score 94.30.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.0206 / max 325.6148, expressed in 1576 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
158255	3.7762	1343
158254	1.5274	800
158249	1.4532	728
158251	0.9984	501
158253	0.6014	347
158250	0.4984	257
158252	0.1453	59
158248	0.0201	5

Top tissues by expression

251 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cerebellar vermis	UBERON:0004720	94.30	gold quality
placenta	UBERON:0001987	89.81	gold quality
ileal mucosa	UBERON:0000331	88.78	gold quality
middle temporal gyrus	UBERON:0002771	88.47	gold quality
adult organism	UBERON:0007023	87.14	gold quality
Brodmann (1909) area 46	UBERON:0006483	87.03	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.97	gold quality
Brodmann (1909) area 23	UBERON:0013554	86.78	gold quality
epithelial cell of pancreas	CL:0000083	86.73	silver quality
kidney epithelium	UBERON:0004819	86.46	silver quality
jejunal mucosa	UBERON:0000399	86.02	gold quality
cauda epididymis	UBERON:0004360	85.51	gold quality
superior frontal gyrus	UBERON:0002661	85.12	gold quality
postcentral gyrus	UBERON:0002581	84.68	gold quality
parietal lobe	UBERON:0001872	84.51	gold quality
entorhinal cortex	UBERON:0002728	84.12	gold quality
cerebellum	UBERON:0002037	83.45	gold quality
prostate gland	UBERON:0002367	83.05	gold quality
cerebellar cortex	UBERON:0002129	82.69	gold quality
cerebellar hemisphere	UBERON:0002245	82.47	gold quality
substantia nigra pars compacta	UBERON:0001965	81.65	gold quality
right hemisphere of cerebellum	UBERON:0014890	81.29	gold quality
superior vestibular nucleus	UBERON:0007227	81.25	gold quality
pancreatic ductal cell	CL:0002079	80.80	gold quality
seminal vesicle	UBERON:0000998	80.53	gold quality
bone marrow cell	CL:0002092	80.45	gold quality
pons	UBERON:0000988	80.39	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	80.07	gold quality
endometrium	UBERON:0001295	79.92	gold quality
stromal cell of endometrium	CL:0002255	79.84	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	4.31

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

344 targeting CDYL2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-126-5P	100.00	72.71	3180
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-3120-5P	100.00	65.56	965
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-10401-5P	99.99	65.79	948
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-6870-5P	99.99	68.55	2115

Literature-anchored findings (GeneRIF, showing 4)

• Discrete functional and mechanistic roles of chromodomain Y-like 2 (CDYL2) transcript variants in breast cancer growth and metastasis. (PMID:32373210)
• circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer. (PMID:34980129)
• STAT5A modulates CDYL2/SLC7A6 pathway to inhibit the proliferation and invasion of hepatocellular carcinoma by targeting to mTORC1. (PMID:35314791)
• Chromodomain on Y-like 2 (CDYL2) implicated in mitosis and genome stability regulation via interaction with CHAMP1 and POGZ. (PMID:36658409)

Cross-species orthologs

11 orthologs

Organism	Symbol	Gene ID
mus_musculus	Cdyl2	ENSMUSG00000031758
rattus_norvegicus	Cdyl2	ENSRNOG00000042888
drosophila_melanogaster	CG14787	FBGN0027793
drosophila_melanogaster	CG8778	FBGN0033761
drosophila_melanogaster	Dci	FBGN0035169
drosophila_melanogaster	HIPP1	FBGN0037027
drosophila_melanogaster	Srlp	FBGN0038049
drosophila_melanogaster	CG5611	FBGN0039531
caenorhabditis_elegans		WBGENE00001152
caenorhabditis_elegans		WBGENE00001154
caenorhabditis_elegans		WBGENE00007130

Paralogs (13): ECHDC1 (ENSG00000093144), ECH1 (ENSG00000104823), ECHDC2 (ENSG00000121310), ECHS1 (ENSG00000127884), CDY2B (ENSG00000129873), ECHDC3 (ENSG00000134463), AUH (ENSG00000148090), CDYL (ENSG00000153046), ECI1 (ENSG00000167969), CDY1 (ENSG00000172288), CDY1B (ENSG00000172352), CDY2A (ENSG00000182415), HIBCH (ENSG00000198130)

Protein

Protein identifiers

Chromodomain Y-like protein 2 — Q8N8U2 (reviewed: Q8N8U2)

All UniProt accessions (2): A0A0B4J291, Q8N8U2

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Interacts (via chromo domain) with histone H3K9me3.

Subcellular location. Nucleus.

Tissue specificity. Ubiquitously expressed.

RefSeq proteins (1): NP_689555* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000953	Chromo/chromo_shadow_dom	Domain
IPR001753	Enoyl-CoA_hydra/iso	Domain
IPR014748	Enoyl-CoA_hydra_C	Homologous_superfamily
IPR016197	Chromo-like_dom_sf	Homologous_superfamily
IPR023779	Chromodomain_CS	Conserved_site
IPR023780	Chromo_domain	Domain
IPR029045	ClpP/crotonase-like_dom_sf	Homologous_superfamily
IPR051053	ECH/Chromodomain_protein	Family

Pfam: PF00378, PF00385

UniProt features (15 total): strand 4, helix 3, compositionally biased region 3, chain 1, domain 1, region of interest 1, sequence conflict 1, turn 1

Structure

Experimental structures (PDB)

8 structures.

PDB	Method	Resolution (Å)
8SP6	X-RAY DIFFRACTION	1.45
4HAE	X-RAY DIFFRACTION	2
5JJZ	X-RAY DIFFRACTION	2
6V2D	X-RAY DIFFRACTION	2.1
6V2H	X-RAY DIFFRACTION	2.6
6V3N	X-RAY DIFFRACTION	2.7
6V8W	X-RAY DIFFRACTION	2.8
2MJ8	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N8U2-F1	72.08	0.50

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 186 (showing top): PEREZ_TP63_TARGETS, MARSON_BOUND_BY_FOXP3_STIMULATED, PAX2_02, GSE13887_HEALTHY_VS_LUPUS_RESTING_CD4_TCELL_UP, GOMF_TRANSCRIPTION_COREPRESSOR_ACTIVITY, ZHAN_MULTIPLE_MYELOMA_MS_UP, KAMMINGA_SENESCENCE, DUTERTRE_ESTRADIOL_RESPONSE_6HR_DN, DUTERTRE_ESTRADIOL_RESPONSE_24HR_DN, BHAT_ESR1_TARGETS_NOT_VIA_AKT1_DN, BHAT_ESR1_TARGETS_VIA_AKT1_DN, GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS, PLASARI_TGFB1_TARGETS_10HR_UP, FORTSCHEGGER_PHF8_TARGETS_DN, DURAND_STROMA_S_UP

GO Biological Process (2): chromatin organization (GO:0006325), negative regulation of DNA-templated transcription (GO:0045892)

GO Molecular Function (4): transcription corepressor activity (GO:0003714), histone H3K27me3 reader activity (GO:0061628), histone H3K9me2/3 reader activity (GO:0062072), protein binding (GO:0005515)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
histone H3 reader activity	2
cellular component organization	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
transcription coregulator activity	1
negative regulation of DNA-templated transcription	1
binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

2668 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CDYL2	E7ERQ6	E7ERQ6	610
CDYL2	VCY	O14598	606
CDYL2	DAZ1	Q9NQZ3	593
CDYL2	DAZ2	Q13117	572
CDYL2	CBX7	O95931	530
CDYL2	CBX2	Q14781	454
CDYL2	CLEC3A	O75596	443
CDYL2	CBX3	Q13185	437
CDYL2	CBX4	O00257	428
CDYL2	CBX8	Q9HC52	420
CDYL2	CDYL	Q9Y232	416
CDYL2	CBX6	O95503	410
CDYL2	XKRX	Q6PP77	406
CDYL2	HOXB7	P09629	404
CDYL2	DAZL	Q92904	393

IntAct

30 interactions, top by confidence:

A	B	Type	Score
CDYL2	ZBTB9	psi-mi:“MI:0915”(physical association)	0.560
HSF2BP	CDYL2	psi-mi:“MI:0915”(physical association)	0.560
CDYL2	DVL3	psi-mi:“MI:0915”(physical association)	0.560
SPANXN2	CDYL2	psi-mi:“MI:0915”(physical association)	0.560
CDYL2	LMO3	psi-mi:“MI:0915”(physical association)	0.560
CDYL2	NXF1	psi-mi:“MI:0915”(physical association)	0.560
CDYL2	PRMT5	psi-mi:“MI:0915”(physical association)	0.510
CDYL2	HSP90B1	psi-mi:“MI:0915”(physical association)	0.400
ZSCAN5A	MRPS12	psi-mi:“MI:0914”(association)	0.350
Cct4		psi-mi:“MI:0914”(association)	0.350
HUWE1	NCOA4	psi-mi:“MI:0914”(association)	0.350
WIZ	RPP30	psi-mi:“MI:0914”(association)	0.350
Wiz	CLNS1A	psi-mi:“MI:0914”(association)	0.350
YEATS4	ING3	psi-mi:“MI:0914”(association)	0.350
NCBP3	RSL1D1	psi-mi:“MI:0914”(association)	0.350
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350
ZBTB9	CDYL2	psi-mi:“MI:0915”(physical association)	0.000
HSF2BP	CDYL2	psi-mi:“MI:0915”(physical association)	0.000
DVL3	CDYL2	psi-mi:“MI:0915”(physical association)	0.000
SPANXN2	CDYL2	psi-mi:“MI:0915”(physical association)	0.000
LMO3	CDYL2	psi-mi:“MI:0915”(physical association)	0.000
NXF1	CDYL2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (28): CDYL2 (Affinity Capture-RNA), CDYL2 (Affinity Capture-RNA), CDYL2 (Protein-peptide), CDYL2 (Affinity Capture-MS), CDYL2 (Affinity Capture-MS), CDYL2 (Affinity Capture-MS), CDYL2 (Affinity Capture-MS), CDYL2 (Affinity Capture-MS), CDYL2 (Affinity Capture-MS), CDYL2 (Affinity Capture-RNA), CDYL2 (Affinity Capture-MS), CDYL2 (Affinity Capture-RNA), CDYL2 (Two-hybrid), CDYL2 (Two-hybrid), CDYL2 (Two-hybrid)

ESM2 similar proteins: A0A1P8ASY1, C0SUU8, C0SV12, C6KIE6, F4HZD1, F4I240, F4I6G4, F4I9Q5, O23463, O64752, O65312, O75164, P0CB22, P29375, Q0WVD6, Q30DN6, Q3UXZ9, Q5BPT4, Q5XUN4, Q62240, Q6K431, Q80Y84, Q84RR2, Q86VD1, Q8BMD7, Q8GUI6, Q8H1E8, Q8H1S7, Q8L7T6, Q8N8U2, Q8VCD7, Q8VY10, Q8VYB9, Q8W595, Q8WML3, Q92794, Q9BY66, Q9C5X4, Q9C6G0, Q9FKV5

Diamond homologs: A0A0P0VUY4, B1Q3J6, C0SQ89, D4ZX35, G3V8T1, J9VQZ0, O23273, O33481, O49139, P13864, P16668, P23737, P25265, P26358, P31033, P34881, P50196, Q24K09, Q27746, Q3TYA6, Q57983, Q5KQL9, Q7Y1I7, Q8LPU5, Q8N8U2, Q92072, Q94F87, Q94F88, Q99549, Q9ARI6, Q9AXT8, Q9M0S8, Q9T0I1, Q9WTK2, O60016, O95931, P05205, P23198, P29227, P30658

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

90 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	73
Likely benign	1
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

2101 predictions. Top by Δscore:

Variant	Effect	Δscore
16:80604395:T:TA	donor_gain	1.0000
16:80604407:T:TA	donor_gain	1.0000
16:80604547:C:CA	acceptor_loss	1.0000
16:80604548:T:G	acceptor_loss	1.0000
16:80608085:AACTC:A	donor_loss	1.0000
16:80608086:ACTC:A	donor_loss	1.0000
16:80608087:CTCA:C	donor_loss	1.0000
16:80608088:TCACC:T	donor_loss	1.0000
16:80608089:CACCA:C	donor_loss	1.0000
16:80608090:A:AC	donor_gain	1.0000
16:80608091:C:CC	donor_gain	1.0000
16:80608091:C:T	donor_loss	1.0000
16:80608091:CCA:C	donor_gain	1.0000
16:80608232:TGGC:T	acceptor_gain	1.0000
16:80608236:C:CC	acceptor_gain	1.0000
16:80620757:GCTCA:G	donor_loss	1.0000
16:80620758:CTCA:C	donor_loss	1.0000
16:80620759:TCACC:T	donor_loss	1.0000
16:80620760:CACCT:C	donor_loss	1.0000
16:80620761:A:AC	donor_gain	1.0000
16:80620762:C:CC	donor_gain	1.0000
16:80620941:G:T	acceptor_gain	1.0000
16:80620943:C:CT	acceptor_gain	1.0000
16:80633241:C:CT	acceptor_gain	1.0000
16:80633241:C:T	acceptor_gain	1.0000
16:80633247:C:CT	acceptor_gain	1.0000
16:80604418:G:C	donor_gain	0.9900
16:80604544:CAC:C	acceptor_gain	0.9900
16:80604547:C:CC	acceptor_gain	0.9900
16:80608090:AC:A	donor_gain	0.9900

AlphaMissense

3326 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:80604453:A:G	W486R	1.000
16:80604453:A:T	W486R	1.000
16:80604477:C:T	E478K	1.000
16:80604518:C:G	R464P	1.000
16:80604529:T:A	K460N	1.000
16:80604529:T:G	K460N	1.000
16:80604530:T:A	K460I	1.000
16:80604531:T:C	K460E	1.000
16:80604534:A:G	S459P	1.000
16:80608120:A:T	V445D	1.000
16:80608132:A:T	V441D	1.000
16:80608157:A:G	W433R	1.000
16:80608157:A:T	W433R	1.000
16:80608162:A:T	V431D	1.000
16:80608169:A:G	S429P	1.000
16:80608171:A:T	V428E	1.000
16:80608174:A:G	L427P	1.000
16:80608174:A:T	L427Q	1.000
16:80608177:C:T	G426E	1.000
16:80608178:C:A	G426W	1.000
16:80608189:G:T	A422D	1.000
16:80608190:C:G	A422P	1.000
16:80608198:G:T	A419D	1.000
16:80608204:A:G	L417P	1.000
16:80608222:A:G	L411P	1.000
16:80612636:C:A	G403V	1.000
16:80612637:C:G	G403R	1.000
16:80612665:G:C	C393W	1.000
16:80612667:A:G	C393R	1.000
16:80612669:C:T	G392D	1.000

dbSNP variants (sampled 300 via entrez): RS1000000312 (16:80764937 G>A), RS1000002934 (16:80666523 C>T), RS1000007276 (16:80703833 G>A,C), RS1000038893 (16:80627693 T>C), RS1000047289 (16:80614186 A>G), RS1000059517 (16:80703988 G>C), RS1000100389 (16:80761052 A>C), RS1000106791 (16:80671017 G>A,T), RS1000116845 (16:80647245 G>C,T), RS1000125863 (16:80656768 C>G,T), RS1000131039 (16:80769654 A>G), RS1000148715 (16:80729244 G>A), RS1000159254 (16:80651352 T>C), RS1000160093 (16:80713760 C>T), RS1000178181 (16:80643120 G>A)

Disease associations

OMIM: gene MIM:618816 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST001937_24	Breast cancer	2.000000e-16
GCST003602_4	Inflammatory bowel disease	2.000000e-08
GCST004988_23	Breast cancer	9.000000e-27
GCST006102_12	Interleukin-10 levels	5.000000e-10
GCST006626_1	Pulse pressure	5.000000e-16
GCST009391_1800	Metabolite levels	1.000000e-07
GCST011535_1	Prostate cancer	5.000000e-07
GCST90011900_143	Serum alkaline phosphatase levels	8.000000e-12
GCST90013406_23	Liver enzyme levels (alkaline phosphatase)	9.000000e-21

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004750	interleukin 10 measurement
EFO:0005763	pulse pressure measurement
EFO:0010529	ribose-5-phosphate measurement
EFO:0010530	ribulose-5-phosphate measurement
EFO:0004533	alkaline phosphatase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3879857 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

60 potent at pChembl≥5 of 94 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.12	IC50	75	nM	CHEMBL3987134
7.08	IC50	84	nM	CHEMBL3978944
7.00	IC50	100	nM	CHEMBL3953637
7.00	IC50	100	nM	CHEMBL3934881
6.96	IC50	110	nM	CHEMBL3943850
6.96	IC50	110	nM	CHEMBL3949885
6.96	IC50	110	nM	CHEMBL3958557
6.96	IC50	110	nM	CHEMBL3972289
6.89	IC50	130	nM	CHEMBL3973366
6.89	IC50	130	nM	CHEMBL3889586
6.85	IC50	140	nM	CHEMBL3939958
6.80	IC50	160	nM	CHEMBL3916023
6.70	IC50	200	nM	CHEMBL3970686
6.58	IC50	260	nM	CHEMBL3937936
6.55	IC50	280	nM	CHEMBL3925993
6.47	IC50	340	nM	CHEMBL3935965
6.47	IC50	340	nM	CHEMBL3944916
6.44	IC50	360	nM	CHEMBL3942693
6.39	IC50	410	nM	CHEMBL3969494
6.38	Kd	415	nM	CHEMBL5715919
6.33	IC50	470	nM	CHEMBL3986571
6.30	IC50	500	nM	CHEMBL3898460
6.27	IC50	540	nM	CHEMBL3966329
6.25	IC50	560	nM	CHEMBL3916999
6.24	IC50	570	nM	CHEMBL3980951
6.23	IC50	590	nM	CHEMBL3985510
6.22	Kd	600	nM	CHEMBL4590713
6.19	Kd	640	nM	CHEMBL4168117
6.17	IC50	670	nM	CHEMBL3974828
6.13	IC50	740	nM	CHEMBL3933207
6.12	IC50	750	nM	CHEMBL3905193
6.07	Kd	850	nM	CHEMBL3939958
6.00	IC50	1000	nM	CHEMBL3970021
5.96	IC50	1100	nM	CHEMBL3945426
5.75	IC50	1800	nM	CHEMBL3955176
5.68	Kd	2100	nM	CHEMBL4435384
5.64	IC50	2300	nM	CHEMBL3978346
5.60	IC50	2500	nM	CHEMBL3946489
5.57	Kd	2700	nM	CHEMBL4460103
5.55	IC50	2800	nM	CHEMBL3954152
5.55	Kd	2800	nM	CHEMBL4513804
5.52	IC50	3000	nM	CHEMBL3907836
5.47	Kd	3400	nM	CHEMBL4435053
5.47	Kd	3400	nM	CHEMBL4469115
5.42	Kd	3800	nM	CHEMBL4582102
5.37	Kd	4300	nM	CHEMBL4442014
5.33	Kd	4700	nM	CHEMBL4531061
5.30	IC50	5000	nM	CHEMBL3932467
5.30	Kd	5000	nM	CHEMBL4542090
5.28	Kd	5300	nM	CHEMBL4581291

PubChem BioAssay actives

58 with measured affinity, of 106 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-3-[4-(aminomethyl)phenyl]-2-[(4-tert-butylbenzoyl)amino]propanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-(diethylamino)hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.0750	uM
methyl (2S)-2-[[(2S)-6-(diethylamino)-2-[[(2S)-4-methyl-2-[[(2S)-2-[[(2S)-2-[(2-naphthalen-2-ylacetyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.0840	uM
methyl (2S)-2-[[(2S)-6-(diethylamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-ethylbenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.1000	uM
methyl (2S)-2-[[(2S)-6-(diethylamino)-2-[[(2S)-4-methyl-2-[[(2S)-2-[[(2S)-3-phenyl-2-[(4-propan-2-ylbenzoyl)amino]propanoyl]amino]propanoyl]amino]pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.1000	uM
methyl 4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-(diethylamino)-1-[[(2S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]benzoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.1100	uM
methyl (2S)-2-[[(2S)-6-(diethylamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-(1H-indol-3-yl)acetyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.1100	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-tert-butylbenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-[propan-2-yl(propyl)amino]hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.1100	uM
[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-tert-butylbenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-[[(2S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl]amino]-6-oxohexyl]-trimethylazanium	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.1100	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-tert-butylbenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-[ethyl(propan-2-yl)amino]hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.1300	uM
methyl (2S)-2-[[(2S)-6-(diethylamino)-2-[[(2S)-4-methyl-2-[[(2S)-2-[[(2S)-3-phenyl-2-[[4-(trifluoromethyl)benzoyl]amino]propanoyl]amino]propanoyl]amino]pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.1300	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-tert-butylbenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-(diethylamino)hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.1400	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-tert-butylbenzoyl)amino]-3-[4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]phenyl]propanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-(diethylamino)hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.1600	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-(4-tert-butylphenyl)acetyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-(diethylamino)hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.2000	uM
methyl (2S)-2-[[(2S)-6-(diethylamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-methoxybenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.2600	uM
methyl (2S)-2-[[(2S)-6-(diethylamino)-2-[[(2S)-4-methyl-2-[[(2S)-2-[[(2S)-2-[(4-methylbenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.2800	uM
methyl (2S)-2-[[(2S)-6-(diethylamino)-2-[[(2S)-4-methyl-2-[[(2S)-2-[[(2S)-2-[(3-methylbenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.3400	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-benzamido-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-(diethylamino)hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.3400	uM
4-tert-butyl-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-(diethylamino)-1-[[(2S)-1-(dimethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]benzamide	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.3600	uM
4-tert-butyl-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-(diethylamino)-1-(2-hydroxyethylamino)-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]benzamide	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.4100	uM
[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[benzoyl(methyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-[[(2S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl]amino]-6-oxohexyl]-trimethylazanium	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.4700	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-tert-butylbenzoyl)amino]-3-phenylpropanoyl]amino]butanoyl]amino]-4-methylpentanoyl]amino]-6-(diethylamino)hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.5000	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-benzamidoacetyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-piperidin-1-ylhexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.5400	uM
methyl (2S)-2-[[(2S)-6-(diethylamino)-2-[[(2S)-4-methyl-2-[[(2S)-2-[[(2S)-2-[(2-methylbenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.5600	uM
[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-benzamido-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-[[(2S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl]amino]-6-oxohexyl]-trimethylazanium	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.5700	uM
methyl (2S)-2-[[(2S)-6-(azepan-1-yl)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-benzamidoacetyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.5900	uM
5-bromo-3-(2-naphthalen-2-yl-2-oxoethyl)-1,3-benzoxazol-2-one	1565815: Binding affinity to recombinant human N-terminal GST-tagged CDYL2 (1 to 70 residues) expressed in Escherichia coli BL2 by SPR analysis	kd	0.6000	uM
N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-6-[ethyl(propan-2-yl)amino]-1-oxohexan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]cyclohexanecarboxamide	1506838: Binding affinity to C-terminal His-tagged CDYL2 (1 to 75 residues) (unknown origin) expressed in Rosetta2 BL21(DE3)pLysS cells by ITC method	kd	0.6400	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-benzamidoacetyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-(diethylamino)hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.6700	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-tert-butylbenzoyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-(diethylamino)hexanoyl]amino]-3-hydroxypropanoic acid	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.7400	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(4-tert-butylbenzoyl)amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-6-(diethylamino)hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	0.7500	uM
[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-benzamidoacetyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-[[(2S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl]amino]-6-oxohexyl]-trimethylazanium	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	1.0000	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-benzamidoacetyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-pyrrolidin-1-ylhexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	1.1000	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-benzamidoacetyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-[di(cyclobutyl)amino]hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	1.8000	uM
5-methoxy-3-[2-oxo-2-(4-pyrrolidin-1-ylpiperidin-1-yl)ethyl]-1,3-benzoxazol-2-one	1565815: Binding affinity to recombinant human N-terminal GST-tagged CDYL2 (1 to 70 residues) expressed in Escherichia coli BL2 by SPR analysis	kd	2.1000	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-benzamidoacetyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	2.3000	uM
[[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-benzamidoacetyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-[[(2S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-(dimethylamino)methylidene]-dimethylazanium	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	2.5000	uM
3-[2-(1H-indol-3-yl)-2-oxoethyl]-1,3-benzoxazol-2-one	1565815: Binding affinity to recombinant human N-terminal GST-tagged CDYL2 (1 to 70 residues) expressed in Escherichia coli BL2 by SPR analysis	kd	2.7000	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-benzamidoacetyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-(dimethylamino)hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	2.8000	uM
3-[2-(1H-indol-3-yl)-2-oxoethyl]-2-oxo-1,3-benzoxazole-5-carbonitrile	1565815: Binding affinity to recombinant human N-terminal GST-tagged CDYL2 (1 to 70 residues) expressed in Escherichia coli BL2 by SPR analysis	kd	2.8000	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-benzamidoacetyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-(cyclopentylamino)hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	3.0000	uM
5-methoxy-3-[2-(3-methoxyphenyl)-2-oxoethyl]-1,3-benzoxazol-2-one	1565815: Binding affinity to recombinant human N-terminal GST-tagged CDYL2 (1 to 70 residues) expressed in Escherichia coli BL2 by SPR analysis	kd	3.4000	uM
3-[2-[4-(diethylamino)piperidin-1-yl]-2-oxoethyl]-5-fluoro-1,3-benzoxazol-2-one	1565815: Binding affinity to recombinant human N-terminal GST-tagged CDYL2 (1 to 70 residues) expressed in Escherichia coli BL2 by SPR analysis	kd	3.4000	uM
3-[2-(1H-indol-3-yl)-2-oxoethyl]-6-nitro-1,3-benzothiazol-2-one	1565815: Binding affinity to recombinant human N-terminal GST-tagged CDYL2 (1 to 70 residues) expressed in Escherichia coli BL2 by SPR analysis	kd	3.8000	uM
(3Z)-5-chloro-3-[2-(3-methoxyphenyl)-2-oxoethylidene]-1H-indol-2-one	1565815: Binding affinity to recombinant human N-terminal GST-tagged CDYL2 (1 to 70 residues) expressed in Escherichia coli BL2 by SPR analysis	kd	4.3000	uM
3-[2-[4-(diethylamino)piperidin-1-yl]-2-oxoethyl]-1,3-benzoxazol-2-one	1565815: Binding affinity to recombinant human N-terminal GST-tagged CDYL2 (1 to 70 residues) expressed in Escherichia coli BL2 by SPR analysis	kd	4.7000	uM
methyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-benzamidoacetyl)amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-6-(2-bicyclo[2.2.1]heptanylamino)hexanoyl]amino]-3-hydroxypropanoate	1319521: Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	ic50	5.0000	uM
3-[2-(3,4-dimethoxyphenyl)-2-oxoethyl]-5-methoxy-1,3-benzoxazol-2-one	1565815: Binding affinity to recombinant human N-terminal GST-tagged CDYL2 (1 to 70 residues) expressed in Escherichia coli BL2 by SPR analysis	kd	5.0000	uM
5-nitro-3-[2-oxo-2-(4-pyrrolidin-1-ylpiperidin-1-yl)ethyl]-1,3-benzoxazol-2-one	1565815: Binding affinity to recombinant human N-terminal GST-tagged CDYL2 (1 to 70 residues) expressed in Escherichia coli BL2 by SPR analysis	kd	5.2000	uM
3-[2-(3,4-dimethoxyphenyl)-2-oxoethyl]-1,3-benzoxazol-2-one	1565815: Binding affinity to recombinant human N-terminal GST-tagged CDYL2 (1 to 70 residues) expressed in Escherichia coli BL2 by SPR analysis	kd	5.3000	uM
N-naphthalen-1-yl-2-(2-oxo-1,3-benzoxazol-3-yl)acetamide	1565815: Binding affinity to recombinant human N-terminal GST-tagged CDYL2 (1 to 70 residues) expressed in Escherichia coli BL2 by SPR analysis	kd	5.8000	uM

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases methylation, affects methylation, decreases expression	3
Estradiol	affects cotreatment, increases expression, decreases expression, decreases reaction	2
aristolochic acid I	decreases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
butyraldehyde	increases expression	1
potassium chromate(VI)	decreases expression	1
aflatoxin B2	increases methylation	1
pentanal	increases expression	1
monomethylpropion	increases expression	1
3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone	affects response to substance	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
2,3,5-trichloro-6-phenyl-(1,4)benzoquinone	increases expression	1
Aldehydes	increases expression	1
Cisplatin	decreases expression	1
Plant Oils	increases expression	1
Dihydrotestosterone	increases expression	1
Testosterone	decreases expression	1
Urethane	increases expression	1
Aflatoxin B1	decreases methylation	1
Gold Compounds	increases expression	1
Okadaic Acid	increases expression	1

ChEMBL screening assays

10 unique, capped per target: 10 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3858696	Binding	Antagonist activity at recombinant human C-terminal His-tagged CDYL2 chromodomain (1 to 75 residues) expressed in Escherichia coli Rosetta BL21(DE3)pLysS using biotin-labeled H3K9me3 measured after 30 mins by AlphaScreen assay	Structure-Activity Relationships and Kinetic Studies of Peptidic Antagonists of CBX Chromodomains. — J Med Chem

Cellosaurus cell lines

3 cell lines: 3 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A0N7	SEES3-1V human CDYL2, clone1	Embryonic stem cell	Male
CVCL_A0N8	SEES3-1V human CDYL2, clone2	Embryonic stem cell	Male
CVCL_A0N9	SEES3-1V human CDYL2, clone3	Embryonic stem cell	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.